Bioinvent: Partner agreements the key to unlocking the case

Research Update

2019-09-20

07:30

The Bioinvent stock has underperformed the broader market during 2019 (-35%), mainly due to the rights issue earlier this year. We believe much negative already is priced in the share, and see a risk/reward skewed towards the upside.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.